4.7 Article

Regulated Expression and Role of c-Myb in the Cardiovascular-Directed Differentiation of Mouse Embryonic Stem Cells

Journal

CIRCULATION RESEARCH
Volume 110, Issue 2, Pages 253-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.111.259499

Keywords

cardiac progenitor cells; embryonic stem cells; smooth muscle differentiation; transcription factors

Funding

  1. Heart and Stroke Richard Lewar Centre of Excellence
  2. Heart and Stroke Foundation of Ontario [CI5503]
  3. Canadian Institutes of Health Research [MOP14648]
  4. Grants-in-Aid for Scientific Research [21591208, 24657157] Funding Source: KAKEN

Ask authors/readers for more resources

Rationale: c-myb null (knockout) embryonic stem cells (ESC) can differentiate into cardiomyocytes but not contractile smooth muscle cells (SMC) in embryoid bodies (EB). Objective: To define the role of c-Myb in SMC differentiation from ESC. Methods and Results: In wild-type (WT) EB, high c-Myb levels on days 0-2 of differentiation undergo ubiquitin-mediated proteosomal degradation on days 2.5-3, resurging on days 4-6, without changing c-myb mRNA levels. Activin-A and bone morphogenetic protein 4-induced cardiovascular progenitors were isolated by FACS for expression of vascular endothelial growth factor receptor (VEGFR) 2 and platelet-derived growth factor receptor (PDGFR)alpha. By day 3.75, hematopoesis-capable VEGFR2+ cells were fewer, whereas cardiomyocyte-directed VEGFR2+/PDGFR alpha+ cells did not differ in abundance in knockout versus WT EB. Importantly, highest and lowest levels of c-Myb were observed in VEGFR2+ and VEGFR2+/PDGFR alpha+ cells, respectively. Proteosome inhibitor MG132 and lentiviruses enabling inducible expression or knockdown of c-myb were used to regulate c-Myb in WT and knockout EB. These experiments showed that c-Myb promotes expression of VEGFR2 over PDGFR alpha, with chromatin immunopreciptation and promoter-reporter assays defining specific c-Myb-responsive binding sites in the VEGFR2 promoter. Next, FACS-sorted VEGFR2+ cells expressed highest and lowest levels of SMC- and fibroblast-specific markers, respectively, at days 7-14 after retinoic acid (RA) as compared with VEGFR2+/PDGFR alpha+ cells. By contrast, VEGFR2+/PDGFR alpha+ cells cultured without RA beat spontaneously, like cardiomyocytes between days 7 and 14, and expressed cardiac troponin. Notably, RA was required to more fully differentiate SMC from VEGFR2+ cells and completely blocked differentiation of cardiomyocytes from VEGFR2+/PDGFR alpha+ cells. Conclusions: c-Myb is tightly regulated by proteosomal degradation during cardiovascular-directed differentiation of ESC, expanding early-stage VEGFR2+ progenitors capable of RA-responsive SMC formation. (Circ Res. 2012;110:253-264.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Chemistry, Multidisciplinary

Photochemically Activated Notch Signaling Hydrogel Preferentially Differentiates Human Derived Hepatoblasts to Cholangiocytes

Muhammad Rizwan, Ana Fokina, Tove Kivijarvi, Mina Ogawa, Markus Kufleitner, Onofrio Laselva, Laura J. Smith, Christine E. Bear, Shinichiro Ogawa, Gordon Keller, Molly S. Shoichet

Summary: Immobilizing jagged1 on chemically defined hyaluronan allows for specific differentiation of human embryonic stem cell-derived hepatoblasts to cholangiocytes, while a new strategy using photochemical methods achieves spatiotemporal control over Notch signaling for ultimate use in regenerative medicine strategies of the liver.

ADVANCED FUNCTIONAL MATERIALS (2021)

Article Cell & Tissue Engineering

BMP10 Signaling Promotes the Development of Endocardial Cells from Human Pluripotent Stem Cell-Derived Cardiovascular Progenitors

Alexander A. Mikryukov, Amine Mazine, Bei Wei, Donghe Yang, Yifei Miao, Mingxia Gu, Gordon M. Keller

Summary: The embryonic endocardium plays a vital role in early heart development by inducing the formation of trabecular myocardium, the source of valvular cells and part of the coronary vasculature. Human endocardial cells offer unique therapeutic opportunities, such as engineering biological valves and cell-based therapy for damaged hearts. By generating hPSC-derived endothelial cells, key signaling pathways for the development of endocardial cells were identified, with a novel role for BMP10 in lineage specification.

CELL STEM CELL (2021)

Article Engineering, Biomedical

A 3-D human model of complex cardiac arrhythmias

Kenneth Williams, Timothy Liang, Stephane Masse, Safwat Khan, Rupal Hatkar, Gordon Keller, Kumaraswamy Nanthakumar, Sara S. Nunes

Summary: Researchers have developed a robust model of acquired arrhythmia by disrupting cardiomyocyte cell-cell signaling. Within 5 days of treatment, all microtissues exhibited progressive arrhythmias, showing various characteristics associated with arrhythmias.

ACTA BIOMATERIALIA (2021)

Article Engineering, Biomedical

One-Step Formation of Protein-Based Tubular Structures for Functional Devices and Tissues

Wuyang Gao, Nima Vaezzadeh, Kelvin Chow, Haotian Chen, Patricia Lavender, Mark D. Jeronimo, Arianna McAllister, Onofrio Laselva, Jia-Xin Jiang, Blair K. Gage, Shinichiro Ogawa, Arun Ramchandran, Christine E. Bear, Gordon M. Keller, Axel Gunther

Summary: This study demonstrates the continuous conversion of low-concentration ECM protein solutions into tailored tubular structures using a microfabricated printhead. The method allows for scalable manufacture and features good permeability and stretchability.

ADVANCED HEALTHCARE MATERIALS (2021)

Article Multidisciplinary Sciences

Generation of mature compact ventricular cardiomyocytes from human pluripotent stem cells

Shunsuke Funakoshi, Ian Fernandes, Olya Mastikhina, Dan Wilkinson, Thinh Tran, Wahiba Dhahri, Amine Mazine, Donghe Yang, Benjamin Burnett, Jeehoon Lee, Stephanie Protze, Gary D. Bader, Sara S. Nunes, Michael Laflamme, Gordon Keller

Summary: The study established a differentiation strategy for generating structurally, metabolically, and functionally mature compact ventricular cardiomyocytes from human pluripotent stem cells. These cardiomyocytes exhibited metabolic changes indicative of heart failure when challenged with pathological stimuli.

NATURE COMMUNICATIONS (2021)

Article Cardiac & Cardiovascular Systems

In Vitro Matured Human Pluripotent Stem Cell-Derived Cardiomyocytes Form Grafts With Enhanced Structure and Function in Injured Hearts

Wahiba Dhahri, Tamilla Sadikov Valdman, Dan Wilkinson, Elizabeth Pereira, Eylul Ceylan, Naaz Andharia, Beiping Qiang, Hassan Masoudpour, Fanny Wulkan, Elya Quesnel, Wenlei Jiang, Shunsuke Funakoshi, Amine Mazine, M. Juliana Gomez-Garcia, Neda Latifi, Yidi Jiang, Ella Huszti, Craig A. Simmons, Gordon Keller, Michael A. Laflamme

Summary: The study showed that culturing hPSC-CMs on PDMS-lined roller bottles and transplanting these cells into a guinea pig model of myocardial infarction resulted in better structural and functional outcomes compared to conventional immature hPSC-CM populations. The PDMS-matured hPSC-CMs exhibited increased cardiac gene expression and more mature properties in vitro, and the intracardiac grafts formed with these cells showed enhanced structure and alignment, better electromechanical integration, and improved contractile function. This study provides practical methods for the scaled generation of mature hPSC-CMs and highlights the importance of using more mature cardiomyocytes for cardiac regeneration.

CIRCULATION (2022)

Article Cardiac & Cardiovascular Systems

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

Senthil Selvaraj, Zhuxuan Fu, Philip Jones, Lydia C. Kwee, Sheryl L. Windsor, Olga Ilkayeva, Christopher B. Newgard, Kenneth B. Margulies, Mansoor Husain, Silvio E. Inzucchi, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, David E. Lanfear, Michael E. Nassif, Ali Javaheri, Robert J. Mentz, Mikhail N. Kosiborod, Svati H. Shah

Summary: This study explored the effects of dapagliflozin on metabolic pathways in HFrEF patients, showing an increase in ketone-related and fatty acid metabolite clusters. It also identified metabolic biomarkers associated with adverse HFrEF outcomes, suggesting a potential role for altered ketone and fatty acid biology with sodium-glucose cotransporter-2 inhibitors.

CIRCULATION (2022)

Article Clinical Neurology

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

W. David Strain, Ofir Frenkel, Martin A. James, Lawrence A. Leiter, Soren Rasmussen, Peter M. Rothwell, Maria Sejersten Ripa, Thomas C. Truelsen, Mansoor Husain

Summary: This post hoc analysis found that GLP-1 RA drug semaglutide can reduce stroke risk in patients with type 2 diabetes, especially the risk of small-vessel occlusion, compared to placebo.

STROKE (2022)

Article Cell Biology

Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors

Blair K. Gage, Simone Merlin, Cristina Olgasi, Antonia Follenzi, Gordon M. Keller

Summary: This study develops an efficient method to generate human pluripotent stem cell-derived liver sinusoidal endothelial cell (LSEC) progenitors from specific mesoderm sub-populations. The study shows that venous endothelial cells generated from certain mesoderm sub-populations are more efficient in LSEC engraftment and can secrete bioactive coagulation factor VIII. These findings highlight the importance of mesoderm induction in generating functional LSECs.

CELL REPORTS (2022)

Article Cell & Tissue Engineering

Modeling human multi-lineage heart field development with pluripotent stem cells

Donghe Yang, Juliana Gomez-Garcia, Shunsuke Funakoshi, Thinh Tran, Ian Fernandes, Gary D. Bader, Michael A. Laflamme, Gordon M. Keller

Summary: This study models human heart development using human pluripotent stem cells, revealing the differentiation and progression of different cardiac lineages. The findings demonstrate the conservation of cardiac lineage development between humans and mice, providing important resources for establishing disease models and developing new therapies.

CELL STEM CELL (2022)

Review Cardiac & Cardiovascular Systems

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Nikolaus Marx, Mansoor Husain, Michael Lehrke, Subodh Verma, Naveed Sattar

Summary: Multiple large cardiovascular outcome trials have shown that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce cardiovascular disease risk in patients with type 2 diabetes, including major adverse cardiovascular events and heart failure. These drugs have received strong recommendations in diabetes and cardiology guidelines, but their usage remains low.

CIRCULATION (2022)

Article Endocrinology & Metabolism

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

Vanita R. R. Aroda, Umut Erhan, Peter Jelnes, Juris J. J. Meier, Morten Tind Abildlund, Richard Pratley, Tina Vilsboll, Mansoor Husain

Summary: Glucagon-like peptide-1 receptor agonists, including oral and subcutaneous semaglutide, are effective in improving glycaemic control and reducing cardiovascular risk. This study analyzed adverse events from clinical trials and found that the most common side effects were gastrointestinal disorders, which decreased with continued therapy.

DIABETES OBESITY & METABOLISM (2023)

Article Cardiac & Cardiovascular Systems

Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials

Kashvi Gupta, John A. Spertus, Mary Birmingham, Kensey L. Gosch, Mansoor Husain, Dalane W. Kitzman, Bertram Pitt, Sanjiv J. Shah, James L. Januzzi, Ildiko Lingvay, Javed Butler, Mikhail Kosiborod, David E. Lanfear

Summary: The health status of Black patients with heart failure is worse compared to White patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) can reduce cardiovascular mortality and improve health status in heart failure patients, but it is unclear if the effect is similar across races. The study found that SGLT2i improves health status equally for Black and White patients.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Michael E. Nassif, Sheryl L. Windsor, Kensey Gosch, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, Sanjiv J. Shah, Guillermo Umpierrez, Bethany A. Austin, Sumant Lamba, Taiyeb Khumri, Kavita Sharma, Mikhail N. Kosiborod

Summary: The benefits of SGLT2 inhibitors on symptoms and physical limitations in patients with heart failure are consistent and clinically meaningful across the full range of ejection fraction (EF), according to a pooled analysis of two trials.

CIRCULATION-HEART FAILURE (2023)

Letter Endocrinology & Metabolism

Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials

Subodh Verma, Mansoor Husain, Christian M. Madsen, Lawrence A. Leiter, Anja Birk Kuhlman, Tina Vilsboll, Soren Rasmussen, Peter Libby

DIABETES OBESITY & METABOLISM (2023)

No Data Available